Frequently Asked Questions
The Irritable Bowel Syndrome Market to grow at a CAGR of 12.90% by forecast 2029.
North America region holds the largest share in the market.
The countries covered in the global irritable bowel syndrome (IBS) market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
Major players operating in the irritable bowel syndrome (IBS) market report are Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals In., Bausch Health, Synthetic Biologics, Inc., Ardelyx., Salix Pharmaceuticals, Mallinckrodt., Abbott Laboratories, LEXICON PHARMACEUTICALS, INC, GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Ono Pharmaceutical Co., Ltd., Pfizer Inc, Novartis and Sebela Pharmaceuticals Inc.
